216 related articles for article (PubMed ID: 32790610)
41. Finasteride for hair loss: a review.
Gupta AK; Venkataraman M; Talukder M; Bamimore MA
J Dermatolog Treat; 2022 Jun; 33(4):1938-1946. PubMed ID: 34291720
[TBL] [Abstract][Full Text] [Related]
42. Alterations of gut microbiota composition in post-finasteride patients: a pilot study.
Borgo F; Macandog AD; Diviccaro S; Falvo E; Giatti S; Cavaletti G; Melcangi RC
J Endocrinol Invest; 2021 Jun; 44(6):1263-1273. PubMed ID: 32951160
[TBL] [Abstract][Full Text] [Related]
43. Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.
Takada M; Fujimoto M; Yamazaki K; Takamoto M; Hosomi K
Drug Saf; 2014 Jun; 37(6):421-31. PubMed ID: 24743876
[TBL] [Abstract][Full Text] [Related]
44. Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Providing balanced information to male patients is key.
Prescrire Int; 2016 Oct; 25(175):242. PubMed ID: 30688421
[No Abstract] [Full Text] [Related]
45. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
46. Guidelines on the use of finasteride in androgenetic alopecia.
Mysore V; Shashikumar BM
Indian J Dermatol Venereol Leprol; 2016; 82(2):128-34. PubMed ID: 26924401
[TBL] [Abstract][Full Text] [Related]
47. On call. I have read several news reports that claim finasteride, which I take for my prostate problem, can cause permanent impotence. Should I be concerned?
Kormos W
Harv Mens Health Watch; 2013 Jan; 17(6):2. PubMed ID: 23807950
[No Abstract] [Full Text] [Related]
48. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
49. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
[TBL] [Abstract][Full Text] [Related]
50. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
51. Post-finasteride syndrome - does it really exist?
Maksym RB; Kajdy A; Rabijewski M
Aging Male; 2019 Dec; 22(4):250-259. PubMed ID: 30651009
[TBL] [Abstract][Full Text] [Related]
52. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
[TBL] [Abstract][Full Text] [Related]
53. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
54. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia.
Lin WL; Hsieh YW; Lin CL; Sung FC; Wu CH; Kao CH
Clin Endocrinol (Oxf); 2015 Apr; 82(4):503-8. PubMed ID: 25158777
[TBL] [Abstract][Full Text] [Related]
55. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
Zhou Z; Song S; Gao Z; Wu J; Ma J; Cui Y
Clin Interv Aging; 2019; 14():399-406. PubMed ID: 30863034
[TBL] [Abstract][Full Text] [Related]
56. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
[TBL] [Abstract][Full Text] [Related]
57. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
[TBL] [Abstract][Full Text] [Related]
58. Exploring adverse events of Vilazodone: evidence from the FAERS database.
Jiang Y; Qu Y; Du Z; Ou M; Shen Y; Zhou Q; Tian L; Zhu H
BMC Psychiatry; 2024 May; 24(1):371. PubMed ID: 38755677
[TBL] [Abstract][Full Text] [Related]
59. Safety Profile of Finasteride: Distribution of Adverse Effects According to Structural and Informational Dichotomies of the Mind/Brain.
Motofei IG; Rowland DL; Manea M; Georgescu SR; Păunică I; Sinescu I
Clin Drug Investig; 2017 Jun; 37(6):511-517. PubMed ID: 28161756
[TBL] [Abstract][Full Text] [Related]
60. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
